Share this article
Share this article
LUND, Sweden, Jan. 27, 2021 /PRNewswire/ Hansa Biopharma will publish its Year-End report 2020 at 8:00 CET on February 4, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/2:00pm EST.
The event will be hosted by Hansa Biopharma s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under Events & Webcast, and will also be made available online after the call.
® progressing as planned
Patient recruitment in the two phase 2 studies in AMR and GBS was reinitiated in December 2020
Year-end cash position of SEK 1.4 billion
LUND, Sweden, Jan. 11, 2021 /PRNewswire/ Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2020 and certain preliminary, unaudited key financials for its financial year 2020.
The Company will be participating in the JP Morgan Global Healthcare Conference in San Francisco from January 11 to 14, 2021, with a corporate presentation on Thursday, January 14, at 7:30am EST/13:30 CET.
COVID-19 pandemic
Hansa has an exciting year ahead with the Company s first product being launched in Europe. However, the global COVID-19 pandemic may still adversely impact Hansa Biopharma s operational business and trial activities.
Share this article
Share this article
LUND, Sweden, Dec. 23, 2020 /PRNewswire/ Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company s management team will present at the 39th Annual J.P. Morgan Healthcare Conference 2021.
The company presentation will take place virtually Thursday January 14, 2021 at 7:30 am (EST)/13:30 (CET).
Management will outline Hansa Biopharma s proprietary enzyme technology platform as well as provide a status update on Idefirix
® (imlifidase), which recently obtained conditional approval in the European Union for enabling kidney transplantation in highly sensitized kidney transplant patients. Imlifidase is additionally being evaluated for further use in other transplantation indications as well as investigated in autoimmune indications and as a pretreatment in gene therapy for inactivation of neutralizing antibodies.